2. Search Result
Search Result
Results for "

hypercholesterolemia

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

7

Inhibitory Antibodies

10

Natural
Products

1

Isotope-Labeled Compounds

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0152
    D-Thyroxine

    D-T4

    		 Endogenous Metabolite Metabolic Disease
    D-Thyroxine (D-T4) is an orally active thyroid hormone that inhibits the secretion of TSH. D-Thyroxine can inhibit goiter, promote metamorphosis of tadpoles and influence cholesterol metabolism. D-Thyroxine can be used for the study of hypercholesterolemia .
    D-Thyroxine
  • HY-P99822
    Recaticimab

    SHR-1209

    		 PCSK9 LDLR Metabolic Disease
    Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
    Recaticimab
  • HY-P99187
    Bococizumab

    PF-04950615; RN316

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
    Bococizumab
  • HY-114456
    Ganglioside GM3

    		Insulin Receptor Metabolic Disease
    Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia .
    Ganglioside GM3
  • HY-125544
    LY 295427

    Agisterol

    		 LDLR Metabolic Disease
    LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research .
    LY 295427
  • HY-W004580
    5,5'-Dicarboxy-2,2'-bipyridine

    		Biochemical Assay Reagents Cardiovascular Disease
    5,5'-Dicarboxy-2,2'-bipyridine is a niacin derivative, which is promising for research of hypercholesterolemia, hyperlipidemia, and cardiovascular disease .
    5,5'-Dicarboxy-2,2'-bipyridine
  • HY-P99251
    Lodelcizumab

    		PCSK9 Others
    Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia .
    Lodelcizumab
  • HY-114952
    SM-32504

    		Acyltransferase Cardiovascular Disease
    SM-32504 is an effective ACAT inhibitor that can significantly reduce serum cholesterol levels in mouse models fed with high-fat and high-cholesterol diets. SM-32504 can be used for research on hypercholesterolemia and atherosclerosis .
    SM-32504
  • HY-124560
    Lifibrol

    		Others Metabolic Disease
    Lifibrol is a potent and oral activity hypolipidemic agent. Lifibrol decreases the plasma total cholesterol. Lifibrol has the potential for the research of hypercholesterolemia .
    Lifibrol
  • HY-143252
    CEase-IN-1

    		Cholinesterase (ChE) Metabolic Disease
    CEase-IN-1 (Compound A1H3) is a potent and selective cholesterol esterase (CEase) inhibitor with an IC50 of 0.36 μM. CEase-IN-1 can be used for the research of hypercholesterolemia .
    CEase-IN-1
  • HY-A0152R
    D-Thyroxine (Standard)

    		Endogenous Metabolite Metabolic Disease
    D-Thyroxine (Standard) is the analytical standard of D-Thyroxine (HY-A0152). This product is intended for research and analytical applications. D-Thyroxine (D-T4) is an orally active thyroid hormone that inhibits the secretion of TSH. D-Thyroxine can inhibit goiter, promote metamorphosis of tadpoles and influence cholesterol metabolism. D-Thyroxine can be used for the study of hypercholesterolemia .
    D-Thyroxine (Standard)
  • HY-117466
    FR186054

    		Acyltransferase Metabolic Disease
    FR186054 is an oral active acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor with the IC50 of 99 nM. FR186054 shows hypocholesterolemic effect and can be used for study of hypercholesterolemia and atherosclerosis .
    FR186054
  • HY-126871
    Zaragozic acid D2

    		Farnesyl Transferase Metabolic Disease Cancer
    Zaragozic acid D2 is the inhibitor for squalene synthase and Ras farnesyl-protein transferase (Ras FPTase), with IC50 of 2 nM and 100 nM, respectively. Zaragozic acid D2 is potentially ameliorating hypercholesterolemia and Ras-induced cancer .
    Zaragozic acid D2
  • HY-117832
    Pyripyropene A
    1 Publications Verification

    		 Acyltransferase Infection Cardiovascular Disease Inflammation/Immunology
    Pyripyropene A is an orally active, potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC50 of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo .
    Pyripyropene A
  • HY-169813
    Yakuchinone B

    		Acyltransferase Cardiovascular Disease
    Yakuchinone B is an Acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitor with hypocholesterolemic activity, which is found in the seeds of Zingiberaceae. Yakuchinone B inhibits rat hepatic ACAT with an IC50 value of 20.6 μM. Yakuchinone B is promising for research of hypercholesterolemia and atherosclerosis .
    Yakuchinone B
  • HY-P99696
    Lerodalcibep

    LIB003

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
    Lerodalcibep
  • HY-153452
    PCSK9-IN-16

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-16 is a potent PCSK9 inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research .
    PCSK9-IN-16
  • HY-148687
    SPC5001

    		PCSK9 Cardiovascular Disease
    SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .
    SPC5001
  • HY-148687A
    SPC5001 sodium

    		PCSK9 Cardiovascular Disease
    SPC5001 sodium is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 sodium can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′ .
    SPC5001 sodium
  • HY-143614
    THR-β agonist 3

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .
    THR-β agonist 3
  • HY-143613
    THR-β agonist 2

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .
    THR-β agonist 2
  • HY-142917
    THR-β agonist 4

    		Thyroid Hormone Receptor Metabolic Disease
    THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .
    THR-β agonist 4
  • HY-155668
    HMG-CoA Reductase-IN-1

    		HMG-CoA Reductase (HMGCR) Metabolic Disease
    HMG-CoA Reductase-IN-1 is a HMG-CoA reductase inhibitor. HMG-CoA Reductase-IN-1has high HMGR inhibitory activity and OATP1B1 affinity with pIC50 and pKm values of 8.54 and 1.98, respectively. HMG-CoA Reductase-IN-1 can be used for the research of hypercholesterolemia .
    HMG-CoA Reductase-IN-1
  • HY-147037
    AMPK activator 7

    		AMPK Cardiovascular Disease Metabolic Disease
    AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC50 of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension .
    AMPK activator 7
  • HY-P9930
    Evolocumab
    2 Publications Verification

    AMG 145

    		 NF-κB Ser/Thr Protease Toll-like Receptor (TLR) Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
    Evolocumab
  • HY-P4153
    Enlicitide chloride

    MK-0616 chloride

    		 PCSK9 Cardiovascular Disease
    Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .
    Enlicitide chloride
  • HY-129340
    AS-183

    		Acyltransferase Cardiovascular Disease
    AS-183 is an inhibitor of cholesterol acyltransferase (ACAT) (IC50=0.94 µM). AS-183 also inhibits the formation of cholesterol esters in HepG2, CaCo2 and THP-1 cells with IC50 values ​​of 18.1, 25.5 and 34.5 µM, respectively. AS-183 can be used in the study of atherosclerosis and hypercholesterolemia .
    AS-183
  • HY-173033
    MI-883

    		Constitutive Androstane Receptor Cytochrome P450 Metabolic Disease
    MI-883 is the orally active agonist for Constitutive Androstane Receptor (CAR, EC50=73 nM) and the antagonist for Pregnane X Receptor (PXR, IC50=0.1 μM). MI-883 stimulates CAR LBD assembly (EC50=0.38 µM) and CAR3 variant activation (EC50=0.074 µM), induces CYP2B6 mRNA expression in HepaRG and primary human hepatocytes. MI-883 inhibits basal PXR activity IC50=2.03 µM) in transiently transfected HepG2 cells, blocks CYP3A4 mRNA expression in HepG2. MI-883 regulates cholesterol metabolism and bile acid excretion, improves hypercholesterolemia in mouse models .
    MI-883
  • HY-167717
    (Rac)-Eflucimibe

    (Rac)-F 12511

    		 Endogenous Metabolite Metabolic Disease
    (Rac)-Eflucimibe ((Rac)-F 12511) is an ACAT inhibitor with endogenous hypercholesterolemia modulating activity. (Rac)-Eflucimibe has shown high potency and efficacy as an anti-hypercholesterol compound in different hypercholesterolemia animal models .
    (Rac)-Eflucimibe
  • HY-P10872
    P315V3

    		SARS-CoV Infection
    P315V3 is an pan inhibitor for coronavirus, that inhibits SARS-CoV-2 prototypePT, Delta, BA.1 and BA.4 strain with IC50s of 10.9, 8.9, 8.6, and 2.7 nM. P315V3 exhibits cytotoxicity in Vero cell with CC50 of 4.3 μM. P315V3 exhibits anti-infectious efficacy in mouse models .
    P315V3
  • HY-148626
    CVI-LM001

    		PCSK9 Metabolic Disease
    CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
    CVI-LM001
  • HY-148689
    SPC4061

    		PCSK9 Metabolic Disease
    SPC4061 an antisense nucleotide, is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .
    SPC4061
  • HY-148689A
    SPC4061 sodium

    		PCSK9 Metabolic Disease
    SPC4061 an antisense nucleotide, sodium is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .
    SPC4061 sodium
  • HY-158825
    Cepadacursen sodium

    CIVI007 sodium

    		 PCSK9 Metabolic Disease
    Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia treatment and the prevention of atherosclerotic cardiovascular disease (ASCVD).
    Cepadacursen sodium
  • HY-108764
    Mipomersen sodium
    1 Publications Verification

    ISIS 301012

    		 Apolipoprotein HCV Metabolic Disease
    Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .
    Mipomersen sodium
  • HY-148647
    Mipomersen

    ISIS 301012 free base

    		 Apolipoprotein HCV Infection
    Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .
    Mipomersen
  • HY-100401A
    Pactimibe sulfate

    CS-505

    		 Acyltransferase Cardiovascular Disease
    Pactimibe sulfate (CS-505) is a dual ACAT1/2 inhibitor with IC50s of 4.9 μM and 3.0 μM, respectively. Pactimibe sulfate (CS-505) inhibits ACAT with IC50s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively . Pactimibe sulfate (CS-505) noncompetitively inhibits oleoyl-CoA with a Ki value of 5.6 μM. Moreover, Pactimibe sulfate (CS-505) obviously inhibits cholesteryl ester formation with an IC50 of 6.7 μM. Pactimibe sulfate (CS-505) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity .
    Pactimibe sulfate
  • HY-100401
    Pactimibe

    CS-505 free base

    		 Acyltransferase Cardiovascular Disease
    Pactimibe (CS-505 free base) is a dual ACAT1/2 inhibitor with IC50s of 4.9 μM and 3.0 μM, respectively. Pactimibe (CS-505 free base) inhibits ACAT with IC50s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively . Pactimibe (CS-505 free base) noncompetitively inhibits oleoyl-CoA with a Ki value of 5.6 μM. Moreover, Pactimibe (CS-505 free base) obviously inhibits cholesteryl ester formation with an IC50 of 6.7 μM. Pactimibe (CS-505 free base) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity .
    Pactimibe
  • HY-106938
    Eldacimibe

    WAY-ACA 147

    		 Acyltransferase Cardiovascular Disease Metabolic Disease
    Eldacimibe is an ACAT2 inhibitor. Eldacimibe can lower plasma cholesterol levels by blocking cholesterol absorption and can prevent macrophages from turning into foam cells. Eldacimibe can be used in the study of cardiovascular diseases (atherosclerosis), endocrine and metabolic diseases (hypercholesterolemia) .
    Eldacimibe
  • HY-A0152A
    D-Thyroxine sodium

    D-T4 sodium

    		 Thyroid Hormone Receptor Cardiovascular Disease
    D-thyroxine (D-T4) sodium is an orally active thyroid hormone that inhibits the secretion of TSH. D-thyroxine sodium can inhibit goiter, promote metamorphosis of tadpoles and influence cholesterol metabolism. D-thyroxine sodium can be used for the study of hypercholesterolemia .
    D-Thyroxine sodium
  • HY-P2424
    Cholecystokinin-J

    CCK-J

    		 Calcium Channel Others
    Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca 2+ release .
    Cholecystokinin-J
  • HY-P9928
    Alirocumab
    1 Publications Verification

    REGN 727; SAR 236553

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
    Alirocumab
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    1 Publications Verification

    REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
    Alirocumab (anti-PCSK9)
  • HY-139134
    S-2E

    		HMG-CoA Reductase (HMGCR) Acetyl-CoA Carboxylase Cardiovascular Disease
    S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research .
    S-2E
  • HY-16274
    Lapaquistat acetate

    TAK-475

    		 Farnesyl Transferase Metabolic Disease
    Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .
    Lapaquistat acetate
  • HY-125324
    Squalestatin 3

    		Endogenous Metabolite Cardiovascular Disease
    Squalestatin 3 is a secondary metabolite, which can be isolated from Phoma. Squalestatin 3 is an inhibitor for squalene synthase with an IC50 of 6 nM .
    Squalestatin 3
  • HY-114456S
    Ganglioside GM3-d7

    		Isotope-Labeled Compounds Others Metabolic Disease
    Ganglioside GM3-d7 is deuterium labeled Ganglioside GM3. Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia .
    Ganglioside GM3-d7
  • HY-149971
    XJ02862-S2

    		FXR Inflammation/Immunology
    XJ02862-S2 shows potent FXR agonistic activity. XJ02862-S2 is a promising lead compound for the research of NAFLD .
    XJ02862-S2
  • HY-W018791
    Bifendate
    1 Publications Verification

    DDB

    		 HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein Infection Cardiovascular Disease Cancer
    Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .
    Bifendate
  • HY-111431
    p-Cresyl sulfate
    5 Publications Verification

    p-Tolyl sulfate

    		 JNK p38 MAPK Reactive Oxygen Species Metabolic Disease
    p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways .
    p-Cresyl sulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: